NASDAQ:XBITXBiotech Stock Price, Forecast & News

XBiotech's stock was trading at $10.72 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, XBIT shares have increased by 35.6% and is now trading at $14.54. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XBiotech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for XBiotech.

XBiotech is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for XBiotech.

XBiotech Inc (NASDAQ:XBIT) posted its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.15). View XBiotech's earnings history.

2 brokers have issued 1-year target prices for XBiotech's stock. Their forecasts range from $18.00 to $28.00. On average, they anticipate XBiotech's share price to reach $23.00 in the next year. This suggests a possible upside of 58.2% from the stock's current price. View analysts' price targets for XBiotech.

Headlines about XBIT stock have trended negative this week, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. XBiotech earned a news impact score of -2.1 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about XBiotech.

XBiotech saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 1,980,000 shares, a decrease of 6.6% from the June 15th total of 2,120,000 shares. Based on an average daily volume of 228,300 shares, the days-to-cover ratio is presently 8.7 days. Approximately 14.2% of the company's shares are short sold. View XBiotech's Current Options Chain.

Some companies that are related to XBiotech include I-Mab (IMAB), Y-mAbs Therapeutics (YMAB), Zymeworks (ZYME), Ironwood Pharmaceuticals (IRWD), Zogenix (ZGNX), Intra-Cellular Therapies (ITCI), Epizyme (EPZM), Intercept Pharmaceuticals (ICPT), BELLUS Health (BLUSF), Cytokinetics (CYTK), Karyopharm Therapeutics (KPTI), Mersana Therapeutics (MRSN), Revance Therapeutics (RVNC), Akcea Therapeutics (AKCA) and ZEALAND PHARMA/S (ZEAL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Cidara Therapeutics (CDTX), Micron Technology (MU), Novavax (NVAX), Ocular Therapeutix (OCUL), Sanofi (SNY), Crispr Therapeutics (CRSP), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

(XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of XBIT stock can currently be purchased for approximately $14.54.

XBiotech has a market capitalization of $419.51 million. The biopharmaceutical company earns $668.63 million in net income (profit) each year or ($0.68) on an earnings per share basis. XBiotech employs 56 workers across the globe.

The official website for XBiotech is www.xbiotech.com.

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]